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Gardner and co-workers advanced the hypothesis that the Seascale leukaemia cluster could have been caused by new mutations in
germ cells, induced by paternal preconceptional irradiation (PPI) exposure at the Sellafield nuclear installation. Since evidence has
shown that PPI can increase the de novo germline mutation rate in hypervariable minisatellite loci, we investigated the hypothesis that
sporadic childhood leukaemia might be associated with an increased parental germline minisatellite mutation rate. To test this
hypothesis, we compared de novo germline mutation rates in the hypervariable minisatellite locus, CEB1, in family trios (both parents
and their child) of children with leukaemia (n¼135) compared with unaffected control families (n¼124). The majority of case and
control germline mutations were paternal (94%); the mean paternal germline mutation rates of children with leukaemia (0.083) and
control children (0.156) were not significantly different (odds ratio, 95% confidence interval: 0.50, 0.23–1.08; P¼0.11). There were
no significant differences in case and control parental allele sizes, case and control germline mutation progenitor allele sizes (2.74 vs
2.54kb; P¼0.56), case and control mutant allele sizes (2.71 vs 2.67kb; P¼0.90), mutant allele size changes (0.13 vs 0.26kb; P¼0.10),
or mutational spectra. Within the limitation of the number of families available for study, we conclude that childhood leukaemia is
unlikely to be associated with increased germline minisatellite instability.
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Acute leukaemia accounts for about 30% of childhood malig-
nancies in the UK, with an average incidence rate of 4/100000/year
(Little, 1999; Stiller, 2004). Childhood leukaemia is thought to be
initiated during early development by unrepaired chromosome
breaks in a haemopoietic progenitor exposed to environmental
carcinogens (Greaves, 1997, 1999). However, epidemiological
studies have failed, with one exception, to identify decisively these
carcinogens. This exception involves exposure of the unborn child
to X-rays in utero, which is associated with a B50% increased risk
of childhood leukaemia (Stewart et al, 1956; Stewart and Kneale,
1968; Stewart and Kneale, 1970; Bithell and Stewart, 1975; Doll and
Wakeford, 1997; Wakeford and Little, 2003).
The discovery of an unusual cluster of childhood leukaemia
cases in the village of Seascale, close to the Sellafield nuclear site in
Cumbria, UK, raised concerns about fetal and neonatal exposure to
environmental ionising radiation (IR; reviewed in Beral, Roman
and Bobrow, 1993). To identify the cause of the Seascale cluster
more precisely, a case–control study of children born in the village
compared with those born elsewhere was carried out by Gardner
et al (1990). The findings of this study were interpreted as
suggesting that exposure to IR of fathers working at Sellafield
might be leukaemogenic in their offspring, by a mechanism
involving IR-induced de novo mutations in sperm during the
preconceptional period. This preconceptional irradiation (PPI)
hypothesis suggested a new mechanism of leukaemogenesis in
humans, and was highly controversial, as there was little evidence
from other sources to suggest that childhood leukaemia could
be caused by germline mutation. Moreover, fathers’ radiation
exposure was considered to be insufficient to cause the mutation
rate required for the number of cases observed (Evans, 1990; Doll
et al, 1994; Wakeford et al, 1994). Additionally, there was no
evidence of a germline effect among the children of Japanese
atomic bomb survivors (Kodaira et al, 1995, 2004; Izumi et al,
2003). Furthermore, as radiation damage is randomly distributed
across the genome, PPI should have caused an increase in single
gene disorders (Doll et al, 1994). Although Parker et al (1999)
reported an increased risk of stillbirth in the offspring of men
working at Sellafield exposed to IR, this was not confirmed by
Doyle et al (2000) in a study of nuclear industry workers.
Subsequent to the Gardner study, Dubrova et al (1996) reported
that PPI caused an increased de novo germline mutation rate in
certain human minisatellite tandem repeat DNA loci. Owing to the
high spontaneous germline mutation rate of some minisatellites
(41000 higher than most protein-coding loci), a PPI effect could
be detected in a substantially smaller population than required to
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sdetect mutations in protein-coding loci (Dubrova et al, 1993, 1996,
1997). Studies of two different populations, one exposed to IR from
radionuclide-contaminated land following the Chernobyl accident
(B0.5Gy, Dubrova et al, 1996, 1997, 2002a), the other from the
fallout of nuclear weapons tests (41Sv; Dubrova et al, 2002b),
revealed an approximate doubling in germline minisatellite
mutation rates due to PPI. These and other data suggest that
minisatellite mutation rates may be useful biomarkers of germline
genetic effects caused by environmental mutagens such as IR
(Yauk, 2004; Bouffler et al, 2006). As minisatellites do not appear
to be the direct target of mutagen-induced DNA damage (Dubrova
et al, 1996, 1997), it is thought that they may act as a marker for
general genome sensitivity or instability (Niwa, 2003).
On the basis of the PPI hypothesis for the aetiology of the
Seascale leukaemia cluster (Gardner et al, 1990), and increased de
novo germline minisatellite mutation because of PPI, we surmised
that a proportion of sporadic childhood leukaemias might be
associated with an increase in the rate of new germline
minisatellite mutations owing to undetected exposures of parental
germ cells to mutagens such as radiation. To address this, we
compared germline mutation rates in the hypervariable human
minisatellite, CEB1 (Vergnaud and Denoeud, 2000) in the families
of children with leukaemia (n¼135) and control families
(n¼124), using a sensitive PCR-based minisatellite genotyping
assay.
MATERIALS AND METHODS
Case and control samples
The case families were a cross-sectional series of children with
acute leukaemia (n¼145) treated at Royal Manchester Children’s
Hospital, UK, and their parents (n¼288; two cases were
monozygotic (MZ) twins). Blood samples were obtained from
case children at diagnosis and in remission and from their parents.
Controls were two series of family trios consisting of unaffected
children (n¼124) and their parents (n¼248). One control series
consisted of buccal scrape samples from children (n¼64) and
blood samples from their parents (n¼128), recruited as part of the
UK Childhood Cancer Study (2000) in the North West (NW) of
England. The second control series consisted of blood samples
from children (n¼60) obtained as part of the Avon Longitudinal
Study of Parents and Children (ALSPAC; Jones et al, 2000) and
buccal samples from their parents (n¼120; Ring et al, 2001).
Sample collection and analyses were carried out with the approval
of Local Research Ethics Committees.
Genomic DNA extraction
Genomic DNA (gDNA) was extracted from case and control blood
samples using phenol/chloroform or Nucleon BACC2 genomic
DNA extraction kits (Amersham Biosciences, Chalfont St Giles,
UK). gDNA was extracted from buccal samples using MasterAmpt
Buccal Swab DNA Extraction Kits (Epicentre Technologies,
Madison, USA). DNA concentrations were measured by fluori-
metry on a TBS-380 Mini-Fluorometer (Turner BioSystems Inc.,
Sunnyvale, CA, USA) using a PicoGreen
s (Molecular Probes,
Paisley, UK) based assay.
CEB1 primer sequences and PCR amplification conditions
CEB1 alleles were amplified by PCR using the 30 CEB1 primer P14
(50-ggatcctctcctgtgcctttcct-30) described by Buard et al (1998) and
a5 0 primer, MAR1 (50-gaattttcagtgagagtcggcc-30). MAR1 was
designed for this study to avoid single nucleotide polymorphisms
(SNPs) flanking the CEB1 minisatellite, using the CEB1 sequence
(accession no. AF048727) and SNP information kindly provided by
Dr Jerome Buard (personal communication). Polymerase chain
reactions were performed on an MJ Research DNA Engine
(Waltham, MA, USA) in 50ml reaction mixtures consisting of
1ml of gDNA (50ng) and 0.5ml (2.5 units) of platinum Taq DNA
polymerase high fidelity (Invitrogen, Paisley, UK) added to 48.5ml
of Mg
2þ-titrated PCR master-mix. The PCR master-mix (19.4ml)
was prepared with the following final reagent concentrations:
0.5mM each high-performance liquid chromatography-purified
CEB1 primer (Eurogentec, Southampton, UK), 0.7mM MgSO4
(50mM MgSO4 with platinum Taq DNA polymerase), 0.2mM
dNTPs (PCR nucleotide mix, Amersham Biosciences) 5% (v/v)
DMSO (Sigma, , Dorset, UK), 0.2mgml
 1 bovine serum albumin
(ultra pure, non-acetylated; Ambion, Warrington, UK), and
1 high-fidelity PCR buffer (50 high-fidelity PCR buffer with
platinum Taq DNA polymerase HF). Amplification conditions
were 941C for 1min 30s, 30 cycles at 941C for 15s, 601C for 30s,
701C for 10min, and a final extension step of 701C for 15min.
Electrophoresis
Polymerase chain reaction products containing CEB1 alleles
amplified from the gDNA of family trios (father, mother, and
child) were loaded onto a 40-cm long 0.7% (w/v) agarose gel
(SeaKem LE Agarose, Cambrex BioScience, East Rutherford, NJ,
USA). Gels were run at 2Vcm
 1 in 1 TBE buffer (Crystal Buffers,
Severn Biotech, Kidderminster, UK) for approximately 23h, until
the 400bp marker from the DNA ladder (1kb plus DNA Ladder,
Invitrogen) was about to run off the gel. Few alleles o400bp were
observed, but when present were sized by a shorter gel run.
Multiple ladder lanes were included across each gel to enable the
image analysis software to calculate the gel retardation factor (Rf
value) for any region of the gel, allowing more accurate allele
sizing. Gels were stained with SYBR gold nucleic acid gel stain
(Molecular Probes) in 1 TBE buffer (pH 8.0), the bands being
visualised by UV transillumination on a Gel Doc 2000 instrument
(Bio-Rad, Hemel Hempstead, UK). The captured gel image in TIFF
file format was set up with an image resolution of 38.4pixelscm
 1.
Identification of CEB1 alleles and mutations
Allele typing and mutation detection were performed on the gel
image using Phoretixt 1D Advance software (Nonlinear Dynamics,
Newcastle upon Tyne, UK). Offspring bands (alleles) were deemed
to be germline mutations if no corresponding alleles were detected
in either parent. Band shifts were measured in bps so that allele
sizes could be adjusted for variations in Rf. This was carried out by
placing a simulated band on the gel image at a position 1.5mm
(corresponding to B8pixels) from the band of interest, in the
direction of the progenitor band in the parent. The progenitor
band was taken to be the parental allele closest in size to the
mutant band (Dubrova et al, 1996). If the size of the putative
mutant allele was equal to or larger (for an expansion), or equal to
or smaller (for a deletion), than the simulated band (as measured
in bp), it was classified as a mutation. All mutations detected were
verified by repeat analysis, in which gDNA was re-amplified and
run on a second gel.
Verification of parentage
Biological parentage was verified in case and control families from
NW England with suspected germline mutations using three short
tandem repeat (STR) markers (VWA, TH01, and FGA) from the
FBI combined DNA index system (CODIS) and the minisatellite,
D1S80, as described in the National Institute of Standards and
Technology STR DNA internet database (http://www.cstl.nist.gov/
biotech/strbase/; Ruitberg et al, 2001) and using HLA-DPB1 typing
data already available for families (Taylor et al, 2002). Primer
sequences for STRs were: VWA 50-ccctagtggatgataagaataatcagtatg-30
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sand 50-ggacagatgataaatacataggatggatgg-30; TH01 50-attcaaagggtat
ctgggctctgg-30,5 0-gtgggctgaaaagctcccgattat-30; and FGA 50-attatcca
aaagtcaaatgccccatagg-30,5 0-atcgaaaatatggttattgaagtagctg-30. Primer
sequences for D1S80 were: 50-gtcttgttggagatgcacgtgccccttgc-30,
50-gaaactggcctccaaacactgcccgccg-30 (Kasai et al, 1990). High-
performance liquid chromatography-purified primers were ob-
tained from Eurogentec or Applied Biosystems (Warrington, UK),
the forward primer for each set being labelled at the 50-end with
VIC (VWA), NED (TH01), or 6-FAM (FGA and D1S80). All four
loci were co-amplified and analysed on an ABI-310 genetic
analyser (Applied Biosystems). Reagent concentrations in 20ml
reaction volumes were 1 ReddyMixt PCR master mix with
2.5mM MgCl2 (ABgene, Epsom, UK), 0.25mM each primer and
2.5ngml
 1 DNA. Polymerase chain reaction amplification condi-
tions were 951C for 2min, 30 cycles at 951C for 30s, 631C for 30s,
701C for 2min, and a final extension step of 701C for 5min.
Parentage was verified in mutation carriers if alleles in at least two
of the four tandem-repeat loci were present in parents; DP types
were used as an independent check. Parentage of all ALSPAC
control family trios was verified using four STR loci (D5S818,
D7S820, D13S317, D16S539; http://www.cstl.nist.gov/biotech/
strbase/) by multiplex PCR using GammaSTR kits (Promega,
Southampton, UK) as described by Ong et al (2004).
Data analysis
Case–control CEB1 germline mutation rates were compared by
calculating cross-product odds ratios (ORs) and 95% confidence
intervals (CI) using the RERI program from the linkage utility
package, LINKUTIL, by the Sheehe method (http://linkage.
rockefeller. edu/soft/linkutil/). The 2 2 programme in LINKUTIL
was used to determine P values for case–control differences using
Fisher’s exact test. Mean case–control parental ages and germline
progenitor allele sizes were compared using unpaired t-tests by
Minitab release 13.30. Case–control parental allele size distribu-
tions were compared using the Kolmogorov–Smirnov Z two-
independent samples test. Statistical power was calculated using
nQuery Advisor v2.0 (Statistical Solutions, Cork, Ireland).
RESULTS
Case–control characteristics
A total of 145 leukaemia cases from 144 families were originally
included in the study. Two cases with B-cell precursor ALL (BCP
ALL) were MZ twins and were treated as one case in the analysis.
Control families consisted of 124 unaffected children and their
parents. Nine case families were excluded from the study; five
because of failure to detect CEB1 alleles; four because of non-
parentage, leaving 135 informative case families. Table 1 shows the
number of informative case children with each leukaemia subtype.
B-cell precursor ALL is the predominant subtype (70%), the
majority (68%) of case samples were collected at diagnosis. The
mean age of cases at diagnosis of leukaemia was 5 years 5 months
(range: 0.2–15.0 years). The mean paternal age at the birth of case
children was 30.47(s.d.) 5.4 years; for the control series were the
following, NW: 31.076.3 years; ALSPAC: 3275 years. Mean
maternal ages were: case children 28.575.7 years; NW controls:
29.174.6 years; ALSPAC controls: 3074.1 years. There were no
significant differences between case and control parental ages
(P40.05)
Amplification and genotyping of CEB1 alleles
CEB1 genotyping was carried out by amplifying gDNA in PCR to
levels visible in SYBR gold-stained gels. A very precise Mg
2þ
concentration (to within 0.1mM) was found to be required for
successful amplification and allele discrimination (Figure 1). Using
this method, we obtained an allele amplification efficiency of 90%,
with no amplification artifacts and consistent results in repeat
sample analysis.
Case–control germline mutation rate comparison
Germline mutations were detected in 11 of 135 case and 20 of 124
control children. Representative examples of mutations (one
expansion and one deletion) in two case families are shown in
Figure 2. All case mutations were paternal in origin; two of 21
control mutations were maternal. One control but no cases had a
double, paternal and maternal, mutation. Table 2 shows that there
is no significant difference in parental mutation rates in case
(0.041) and control (0.086) families (OR, 95% CI: 0.47, 0.23–0.98;
P¼0.061). Paternal mutation rates in case (0.083) and control
families (0.156) were also not significantly different (OR, 95% CI:
0.50, 0.23–1.08; P¼0.11). Analysis of mutation rates in relation to
leukaemia subtype (Table 3) shows no significant case–control
differences, though the small number of pro B and T ALL and
acute myeloid leukaemia (AML) suggests that these results should
be treated with caution. The subtype with the highest mutation rate
was T ALL (0.111), but this was not significantly different from
controls (OR, 95% CI: 0.8, 0.22–3.00; P¼0.93). The mean age of
case fathers with a germline mutation (29.9 years) was not
significantly different from NW control fathers with a mutation
Table 1 Details of leukaemia case series in this study
Number of samples obtained at
Leukaemia cases Diagnosis Remission Total
BCP ALL 66 29 95
Pro-B ALL 6 2 8
T ALL 10 9 19
AML
a 11 2 13
Total cases 93 42 135
AML, acute myeloid leukaemia; BCP ALL, B-cell precursor ALL; Pro-B ALL,
progenitor B-cell ALL; T ALL, T-cell ALL.
aOne case of chronic myeloid leukaemia
and one case of myelodysplastic syndrome.
5 kb
2 kb
1 kb
0.8 0.9 1.0
AB
1.1 0.8 0.9 1.0 1.1mM Mg2+
Figure 1 Effect of Mg
2þ concentration on amplification of CEB1 alleles
in two gDNA samples (A and B) by PCR. No alleles were resolved at 0.8
or 1.1mM Mg
2þ, whereas alleles were optimally detected at 0.9–1.0mM.
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had a germline mutation (29.9 years) was not significantly different
from fathers of case children who had no mutation (30.4 years;
P¼0.81). The mean germline mutation rate in diagnostic samples
(0.039) was not significantly different from remission samples
(0.046; P40.05). The CEB1 allele size distributions (Figure 3) in
case parents (mean allele size: 2865bp; 72 repeats) was not
significantly different from control parents (mean allele size:
2360bp; 59 repeats; P40.05).
Germline mutation spectrum
In cases, there were seven (64%) mutant alleles with an increased
and four with a decreased number of repeats, whereas in the
controls, 15 (71%) mutants increased and six decreased in size.
The size of the mutational events was similar in the cases and
3 kb
2 kb
1 kb
4 kb
FC M F CM
AB
Figure 2 Detection of de novo germline CEB1 mutations in two family
trios (A and B) following PCR and gel electrophoresis. Mutant alleles are
indicated by white arrows. Family A has a paternal mutation corresponding
to a seven repeat expansion. Family B has a paternal mutation
corresponding to a one repeat deletion. To ensure accurate band
comparison between adjacent lanes samples were loaded in the order
father (F), child (C), mother (M).
Table 2 Germline CEB1 mutation rate in parents of childhood leukaemia cases and controls
Comparison Cases Controls OR 95% CI Two-sided P*
Informative family trios (n) 135 124
Informative offspring (n) 136 124
Paternal alleles (n) 132 122
Maternal alleles (n) 131 122
Paternal germline mutations 11 19
Maternal germline mutations 0 2
Paternal mutation rate 0.083 (8.3%) 0.156 (15.6%) 0.50 0.23–1.08 0.11
Maternal mutation rate 0 0.016 (1.6%) 0.18 0.02–1.79 0.463
Parental mutation rate 0.041 (4.1%) 0.086 (8.6%) 0.47 0.23–0.98 0.061
CI, confidence interval; n, number; OR, odds ratio. *Two-sided P value in Fisher’s exact test.
Table 3 Paternal CEB1 germline mutation rate in relation to childhood leukaemia subtype
Leukaemia subtype Paternal alleles Paternal mutations Paternal mutation rate OR 95% CI Two-sided P
BCP ALL 93 9 0.097 (9.7%) 0.60 0.27–1.34 0.28
Pro-B ALL 8 0 0 0.31 0.04–2.60 0.54
T ALL 18 2 0.111 (11.1%) 0.80 0.22–0.46 0.93
AML 13 0 0 — — —
Total cases 132 11 0.083 (8.3%) 0.50 0.23–1.08 0.11
Controls 122 19 0.156 (15.6%)
AML, acute myeloid leukaemia; BCP ALL; B-cell precursor ALL; Pro-B ALL, progenitor B-cell ALL; T ALL, T-cell ALL.
aLeukaemia subtype in relation to paternal allele mutation
rate.
0
0.4
0.8
1.2
1.6
225 200 175 150 125 100 75 50 25
9.5 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 3.5 3 2.5 2 1.5 1 0.5
Allele size (repeats / kbp–)
F
r
e
q
u
e
n
c
y
Case parents
Control parents
Figure 3 Size distribution of CEB1 alleles in the parents of case and
control children (number of alleles: case, n¼496; control, n¼457). DNA
fragments were grouped into 0.5kb intervals from 0.5 to 9.5kb, with the
number of repeat units shown, where one consensus repeat¼40bp).
Differences between case and control parent allele distributions were not
significant in the Kolmogorov–Smirnov two-sample test (P40.05).
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significantly different from controls (2.67kb; Po0.90). There was
no difference between mean progenitor allele size in cases (2.74kb)
and controls (2.54kb; P¼0.56). Most mutations (75%) involved
the gain or loss of 1–5 repeat units (Figure 4), but there was no
significant difference in the size change in cases (0.13kb) and
controls (0.25kb; P¼0.10). The largest control mutation was an
expansion of 32 repeat units (progenitor allele size: 2.09kb); the
largest case mutation was a deletion of nine repeats (progenitor
allele size: 2.55kb) in a child with BCP ALL.
DISCUSSION
This study was designed to address the hypothesis that sporadic
childhood leukaemia is associated with an increased rate of de
novo germline mutation in the hypervariable minisatellite, CEB1.
The results show, with some qualifications, that there is no
association. The hypothesis is based on the notion that exposure
of parental germ cells to mutagenic agents such as IR can lead to
an increased risk of childhood leukaemia, the PPI hypothesis
(Gardner et al, 1990). Here, we used minisatellite mutation as a
biomarker of de novo germline leukaemogenic damage. We found
no evidence for quantitative (germline mutation rate) or
qualitative (mutation spectrum) differences in CEB1 minisatellite
mutations between case and control families. As far as we are
aware no previous study of this type has been reported in
childhood leukaemia.
Unlike other studies of germline minisatellite mutation rate in
relation to parental IR exposure (reviewed by Bouffler et al, 2006),
no parental radiation dosimetry data were available for our
leukaemia cases. Accurate environmental radiation and mutagen
exposure data are extremely difficult to collect in a non-
occupational setting, but it is safe to assume in these cases that
environmental radiation exposures were extremely low. The
catchment area for our sporadic cases covers an area of NW
England south of Cumbria, where levels of occupational or
environmental radiation are far below those to which the Sellafield
workers were exposed. As CEB1 exhibits high rates of spontaneous
and induced mutation, our study should have revealed evidence of
undetected parental mutagen exposure associated with childhood
leukaemia. From our prior hypothesis of an increased case de novo
germline mutation rate, our study of 135 informative case and 124
control families has 90% power to detect a significant doubling
(one-sided, P¼0.05) of the control paternal mutation rate in cases
(i.e., from 0.156 in controls to 0.312 in cases). Although we
analysed only one minisatellite locus, in contrast to others using
up to eight loci (reviewed by Bouffler et al, 2006), it is worth noting
that significance in multiple locus tests requires correction for the
number of loci tested, whereas our result does not.
Germline minisatellite mutation analysis has routinely been
carried out using Southern blotting and probing of PCR-amplified
gDNA (Dubrova et al, 1996; Stead and Jeffreys, 2000). However,
this is expensive on gDNA, leading to difficulties in testing
children with haemopoietic malignancies where numbers of
peripheral blood leucocytes may be reduced by disease or therapy.
Using a PCR-based genotyping assay that directly visualised CEB1
alleles on long-read agarose gels using a UV transilluminator,
direct analysis of PCR products has provided a robust alternative,
allowing fine resolution and sizing of mutations. Careful titration
of Mg
2þ gave reproducible amplification of CEB1 alleles to visible
levels, which we found useful for the genotyping of other PCR-able
minisatellite loci such as B6.7 (Tamaki et al, 1999). Several other
hypervariable minisatellites (Vergnaud and Denoeud, 2000) should
be amenable to analysis using this PCR-genotyping assay.
The majority of de novo germline mutations detected in the case
and control series in the present study (30/32) were paternal in
origin, a result previously reported for CEB1 (Vergnaud et al,
1991). We examined the size change and polarity of mutational
events (increase or decrease in allele size), but found no difference
between the case and control series. In both groups, allele size
expansions were more prevalent than deletions (with an overall
ratio of 2.2:1 in favour of expansion) and a large proportion of
mutations involved the gain or loss of only 1–3 repeat units (73
cases and 62% controls). Small mutations such as these are
reminiscent of the stepwise model for microsatellite expansion
(Nag, 2003) though the evidence suggests that virtually all CEB1
germline mutations are initiated by recombinogenic events
occurring during gametogenesis (Buard et al, 1998, 2000) and
not as a result of DNA replication slippage.
In view of the tendency of some single gene disorders to increase
in frequency with paternal age, we compared paternal ages at the
birth of case and control children with germline mutations. There
was no evidence that fathers transmitting germline mutations were
significantly older than those who did not. Although mean allele
sizes differed slightly between cases and controls (72 and 59
repeats, respectively), there was no significant difference between
the allele size distributions suggesting that paternal allele size is
not a factor in the risk of leukaemia. This was confirmed by the
finding that the sizes of the germline mutation progenitor alleles in
cases and controls were not significantly different. The analysis of
CEB1 mutation rate in relation to leukaemia subtype was limited
by the small number of cases with progenitor B-cell ALL, T ALL,
and AML. However, our preliminary finding suggests that none of
the leukaemia subtypes had a mutation rate that was higher than
the controls.
The type of sample used in the CEB1 genotyping was a potential
confounder. We collected 69% of case samples at diagnosis and
31% in remission. The diagnostic samples contained varying
percentages of leukaemic blasts (1–96%), which could have
influenced the result if the blasts contained CEB1 somatic
mutations. However, comparison of the mutation frequency in
the diagnostic (seven mutations in 93 children (7.5%)) and
remission samples (four mutations in 42 children (9.5%)) suggests
little difference. In seven case families, where paired diagnostic and
remission samples were available for analysis, we found no
differences in CEB1 alleles in the paired samples, even though
three of the diagnostic samples had 473% blasts. In the control
families, buccal instead of blood samples were obtained from
children in the NW series and from parents in the ALSPAC series.
The overall germline mutation rate in the two series was little
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Figure 4 Frequency distribution of germline CEB1 mutations in case and
control children by size and polarity, with mutations grouped into repeat
unit changes of up to five units. In leukaemia case children, all gains are 1-5
repeats and losses 1-10 repeats, whereas in control children gains are 1-35
repeats and losses 1-15 repeats.
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sdifferent (0.0833 (NW) and 0.0877 (ALSPAC)), confirming
preliminary studies showing that the genotypes of buccal samples
do not differ from blood. The CEB1 somatic mutation rate is
known to be very low (Vergnaud et al, 1991; Buard et al, 1998;
2000). Buard et al (2000) reported that the CEB1 somatic mutation
rate in blood was 1.8 10
 4 as compared with a B6% germline
mutation rate in the same donor.
In summary, our results show, within the limitations of the
numbers of case and control families available for study, no
evidence of an increased rate of de novo CEB1 germline
minisatellite mutation in the parents of children with sporadic
leukaemia. Our provisional conclusion is that new germline
minisatellite mutations, used as a surrogate measure of parental
mutagen exposure on germ cell stability, are unlikely to be a major
factor in the aetiology of childhood leukaemia. Although our data
do not rule out the possibility that prezygotic mutagenesis could
account for rarer subtypes of childhood leukaemia, approaches to
this question based on population case–control comparisons are
unlikely to have sufficient power to provide a definitive result. The
report by Dickinson and Parker (2002) confirming the original
findings of Gardner et al (1990) of a statistical association between
a father’s radiation dose at Sellafield and the child’s risk of
developing leukaemia suggests that future studies of germline
minisatellite mutations in childhood leukaemia should focus
specifically on case clusters. Thus, the collection of DNA from
family trios in such clusters (Steinberg et al, 2006) has a high
priority.
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